BusinessMoneycontrol
'Finality to a saga': Johnson & Johnson commits $5.5 billion to resolve ovarian cancer claims
in5points
Johnson & Johnson commits $5.5 billion to resolve ovarian cancer claims.
Agreement requires participation of firms representing at least 95% of claims.
Proposal aims to end 15 years of litigation over talc-linked ovarian cancer.
J&J continues to deny the allegations of causing cancer.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Moneycontrol
Center-right
Mixed factuality
